 |
市場調査レポート
商品コード
939994
市場スポットライト：肉腫 (サルコーマ)Market Spotlight: Sarcoma |
||||||
| 市場スポットライト：肉腫 (サルコーマ) |
|
出版日: 2020年10月15日
発行: Datamonitor Healthcare
ページ情報: 英文 55 Pages
納期: 即日から翌営業日
|
当レポートでは、世界の肉腫 (サルコーマ) 治療薬市場について調査分析し、主な上市薬・パイプライン薬、臨床試験、最近の動向、将来の動向、成功確率、特許情報、10ヶ年予測などについて、体系的な情報を提供しています。
This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2019, there were approximately 430,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 503,700 incident cases by 2028.
Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (85%), while a smaller proportion were osteosarcomas and malignant bone tumors (15%).
The approved drugs in the sarcoma space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.
The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular, subretinal, subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, topical, and subcutaneous formulations.
High-impact upcoming events for drugs in the sarcoma space comprise topline Phase II trial results for ADP-A2M4 and topline Phase Ib/II trial results for ABI-009.
The overall likelihood of approval of a Phase I sarcoma asset is 10%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.5 years from Phase I to approval in the sarcoma space as well as in the overall oncology space.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.
The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major European markets, while Israel has the top spot in Asia.
Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co and Novartis have the highest number of completed clinical trials for sarcoma, with 21 trials each.
Merck & Co leads industry sponsors with the highest overall number of clinical trials for sarcoma, followed by Bristol Myers Squibb and Novartis.
比較リスト
